# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The funds will be utilized to finalize the late-stage development and testing of a pre-pandemic mRNA-based vaccine against H5N1...
10 worst performing large-cap stocks last week: Walgreens, Floor & Decor, Moderna, Birkenstock, BeiGene, Pool Corp, JD.com,...
Moderna's RSV vaccine, mRNA-1345, is designed to protect adults aged 60 and older from respiratory disease caused by the RS...
Needham analyst Joseph Stringer reiterates Moderna (NASDAQ:MRNA) with a Hold.
Development Candidate targets Glypican-3 for the treatment of solid tumors, including hepatocellular carcinomaNomination trigge...
Piper Sandler analyst Edward Tenthoff reiterates Moderna (NASDAQ:MRNA) with a Overweight and maintains $214 price target.